Patients on long-term glucocorticoid therapy are at risk of developing which disease?

Patients on long-term glucocorticoid therapy are at an increased risk of developing osteoporosis. Glucocorticoids, which are anti-inflammatory in nature, can negatively impact bone health by inhibiting osteoblast function, which is crucial for bone formation. They also decrease the absorption of calcium from the gastrointestinal tract and increase renal excretion of calcium, leading to a reduction in bone mineral density. Over time, this contributes to bone fragility and an increased risk of fractures.

Understanding the implications of glucocorticoid therapy is vital, as many patients may require long-term treatment for various conditions, including autoimmune disorders and chronic inflammatory diseases. Monitoring bone health and implementing preventive measures, such as calcium and vitamin D supplementation or bisphosphonate therapy, are important considerations for these patients to mitigate the risk of developing osteoporosis.